L 287/22 Official Journal of the European Union 1.10.2014 DECISIONS COUNCIL IMPLEMENTING DECISION of 25 September 2014 on  subjecting  4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine  (251-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxy- pyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures (2014/688/EU) THE COUNCIL OF THE EUROPEAN UNION, Having regard to the Treaty on the Functioning of the European Union, Having regard to Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances ('), and in particular Article 8(3) thereof, Having regard to the proposal from the European Commission, Whereas: (1)  Risk assessment reports on the new psychoactive substances 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl) phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyllmethyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxeta- mine) were drawn up in compliance with Decision 2005/387/JHA by a special session of the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), and were subsequently submitted to the Commission and to the Council on 23 April 2014. (2) 25I-NBOMe, AH-7921, MDPV and methoxetamine had not been under assessment at the United Nations’ level by the time the risk assessment was requested at Union level, but they were evaluated in June 2014 by the Expert Committee on Drug Dependence of the World Health Organization. (3)  25I-NBOMe, AH-7921, MDPV and methoxetamine have no established or acknowledged medical use (human or veterinary). Apart from their use in analytical reference materials, and in scientific research investigating their chemistry, pharmacology and toxicology as a result of their emergence on the drug market — and, in the case of 25I-NBOMe, also in the field of neurochemistry — there is no indication that they are being used for other purposes. (4)  25I-NBOMe is a potent synthetic derivative of 2,5-dimethoxy-4-iodophenethylamine (2C-I), a classical seroto- nergic hallucinogen, which was subject to risk assessment and to control measures and criminal sanctions at Union level from 2003 by Council Decision 2003/847[JHA (). (5)  The specific physical effects of 25I-NBOMe are difficult to determine because there are no published studies asses- sing its acute and chronic toxicity, its psychological and behavioural effects, and dependence potential, and because of the limited information and data available. Clinical observations of individuals who have used this substance suggest that it has hallucinogenic effects and has the potential for inducing severe agitation, confusion, intense auditory and visual hallucinations, aggression, violent accidents and self-induced trauma. () OJL127,20.5.2005, p. 32. (%) Council Decision 2003/847(JHA of 27 November 2003 concerning control measures and criminal sanctions in respect of the new synthetic drugs 2C-I, 2C-T-2, 2C-T-7 and TMA-2 (OJ L 321, 6.12.2003, p. 64).